IMU 9.26% 5.9¢ imugene limited

Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-57

  1. 252 Posts.
    lightbulb Created with Sketch. 84
    My bet is that CF33 will obtain breakthrough therapy status from the FDA at some stage and we'll get to fastrack and miss out on expensive and timely phase 3 registrational studies.

    Hence why we are buying IP to complement CF33, manufacturing facilities and staff.

    IMU gearing up to be a pharmaceutical company, not just a research company.

    Imo dyor.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.